On June 27, the pharmaceutical company Aurobindo Pharma told the stock markets that it had received a “warning letter” from the Securities and Exchange Board of India (SEBI) over the controversy surrounding the US Food and Drug Administration (USFDA) audit at its Hyderabad facility.
Hyderabad, India’s HITEC City serves as the corporate headquarters for the worldwide pharmaceutical manufacturing business Aurobindo Pharma Limited. The business produces both active medicinal components and generic medications.
In the next board meeting, the firm has been requested to present the warning letter to the board of directors, according to the regulatory filing.
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
